---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-070335"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:53:18.039529+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology completes de-SPAC business combination; CTOR begins trading

## Summary
- Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).
- Company Common Stock began trading on Nasdaq Capital Market as 'CTOR' on August 13, 2024.
- Leonard Mazur appointed CEO & Chair; Jaime Bartushak CFO; Myron Holubiak Secretary/Treasurer; Myron Czuczman CMO.
- Citius Pharma contributed $10M capital; waivers include LYMPHIR trademark transfer within 60 days post-closing.
- 71.3M shares outstanding post-closing; board of 8 directors with staggered terms; controlled company under Nasdaq rules.

## SEC filing metadata
- accession: 0001213900-24-070335
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 5.06, 9.01, 5.02, 3.02, 3.03, 4.01, 5.01, 5.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/ea0211423-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-070335
- JSON: https://secwatch.observer/filing/0001213900-24-070335.json
- Plain text: https://secwatch.observer/filing/0001213900-24-070335.txt

## Key facts
- Executive change
  Cathy Jiang resigned as Director at CITIUS ONCOLOGY, INC..
  - Action: resigned
  - Role: Director
  source text: each of Cathy Jiang and Brian Hartzband resigned as directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm
- Executive change
  Brian Hartzband resigned as Director at CITIUS ONCOLOGY, INC..
  - Action: resigned
  - Role: Director
  source text: each of Cathy Jiang and Brian Hartzband resigned as directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm
- Executive change
  Xiaofeng Yuan resigned as Chief Executive Officer at CITIUS ONCOLOGY, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm
- Executive change
  Taylor Zhang resigned as Chief Financial Officer at CITIUS ONCOLOGY, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Taylor Zhang resigned as Chief Financial Officer and a director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.